A 35-year-old woman from Mumbai presents with a 3-week history of fever, malaise, and loose stools. She was treated empirically with ciprofloxacin 500 mg twice daily for 5 days by a local practitioner 2 weeks ago, but fever persisted. On examination, she is febrile (38.8°C), has mild hepatomegaly, and a faint maculopapular rash on the trunk. Blood culture obtained on day 21 of illness grows *Salmonella typhi* susceptible to ceftriaxone but resistant to fluoroquinolone and chloramphenicol. What is the most likely reason for treatment failure with ciprofloxacin?

Explanation

## Mechanism of Fluoroquinolone Resistance in *Salmonella typhi* **Key Point:** Fluoroquinolone resistance in *S. typhi* is mediated by chromosomal mutations in genes encoding DNA gyrase (GyrA, GyrB) and topoisomerase IV (ParC, ParE), not by plasmid-mediated mechanisms. **High-Yield:** In India, the prevalence of fluoroquinolone-resistant *S. typhi* (FQRS) has increased from <5% in 2000 to >50% by 2020. This is a major driver of treatment failures and the shift to cephalosporins as first-line therapy. ## Mechanism of Fluoroquinolone Action and Resistance ```mermaid flowchart TD A[Fluoroquinolone enters cell]:::action --> B[Binds DNA gyrase & topoisomerase IV]:::action B --> C[Inhibits DNA replication & transcription]:::action C --> D{Susceptible strain?}:::decision D -->|Yes| E[Bacterial death]:::outcome D -->|No - Resistant| F[Mutations in GyrA/GyrB/ParC/ParE]:::urgent F --> G[Altered enzyme binding site]:::urgent G --> H[Fluoroquinolone cannot bind effectively]:::urgent H --> I[Continued DNA replication & survival]:::urgent ``` **Clinical Pearl:** Fluoroquinolone resistance in *S. typhi* is **not inducible** (unlike in *Pseudomonas*); it is **pre-existing** due to chromosomal mutations. Treatment failure occurs because the infecting strain is inherently resistant, not because resistance develops during therapy. ## Why This Patient Failed Fluoroquinolone Therapy 1. The infecting *S. typhi* strain carried pre-existing mutations in DNA gyrase and topoisomerase IV genes 2. These mutations altered the enzyme binding sites, preventing fluoroquinolone binding 3. Despite adequate dosing and penetration, the drug could not inhibit DNA replication 4. The organism continued to replicate, causing persistent fever 5. Blood culture on day 21 confirmed the organism was fluoroquinolone-resistant **Mnemonic:** **GYR-PAR** — **GYR**ase (DNA gyrase) and **PAR**C (topoisomerase) mutations = Fluoroquinolone resistance in *S. typhi*. ## Comparison: Resistance Mechanisms in Gram-Negative Pathogens | Mechanism | *S. typhi* | *E. coli* | *Pseudomonas* | |-----------|-----------|----------|---------------| | Chromosomal mutations (GyrA/ParC) | ✓ (primary) | ✓ | ✓ | | Plasmid-mediated (qnr genes) | Rare | Common | Rare | | Efflux pumps | Minor role | Minor role | Major role | | Inducible resistance | No | No | Yes | **High-Yield:** Fluoroquinolone resistance in *S. typhi* is **chromosomal and non-inducible**, making it a treatment failure mechanism rather than a tolerance phenomenon.